Sugi Predict

Sugi Predict / Compounds / SCHEMBL177336

SCHEMBL177336

SCHEMBL177336

CCCOc1ccc(C(=O)O)cc1OC

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.77
▸ CA12 O43570 1/20 0.69
▸ CA1 P00915 1/20 0.69
▸ CA2 P00918 1/20 0.69
▸ CA4 P22748 1/20 0.69
▸ CA6 P23280 1/20 0.69
▸ CA7 P43166 1/20 0.69
▸ TPMT P51580 1/20 0.69
▸ CA9 Q16790 1/20 0.69
▸ CA14 Q9ULX7 1/20 0.69
▸ HPGD P15428 1/20 0.64
▸ HSD17B10 Q99714 1/20 0.64
▸ PLA2G4B P0C869 1/20 0.62
▸ KDM4E B2RXH2 1/20 0.59
▸ MRGPRX4 Q96LA9 1/20 0.59
▸ POLB P06746 1/20 0.57
▸ CASP6 P55212 1/20 0.57
▸ THRA P10827 1/20 0.56
▸ THRB P10828 1/20 0.56
▸ TTR P02766 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7334285 0.94 CA12 (0.69) TSHRCA12CA1CA2CA4
SCHEMBL2329752 0.92 TSHR (0.74) TSHRCA12CA1CA2CA4
SCHEMBL1750327 0.92 TSHR (0.74) TSHRCA12CA1CA2CA4
SCHEMBL8085474 0.92 TSHR (0.78) TSHRCA12CA1CA2CA4
SCHEMBL8122418 0.92 TSHR (0.78) TSHRCA12CA1CA2CA4
SCHEMBL566516 0.92 POLB (0.66) TSHRCA12CA1CA2CA4
SCHEMBL16077692 0.91 PLA2G4B (0.74) TSHRCA12CA1CA2CA4
SCHEMBL18682279 0.91 PLA2G4B (0.74) TSHRCA12CA1CA2CA4
SCHEMBL2312195 0.91 PLA2G4B (0.74) TSHRCA12CA1CA2CA4
SCHEMBL9307551 0.91 PLA2G4B (0.74) TSHRCA12CA1CA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4077325-B1 SELECTIVE CDK4/6 INHIBITOR CANCER THERAPEUTICS LUNELLA BIOTECH INC (CA) 2026-03-11 — — EP disclosed
US-20250304591-A1 SUBSTITUTED PYRROLO[2,3-d]PYRIMIDINES AS SELECTIVE CDK 4/6 INHIBITORS LUNELLA BIOTECH INC (CA) 2025-10-02 — — US disclosed
EP-4165046-B1 SELECTIVE CDK4/6 INHIBITOR CANCER THERAPEUTICS LUNELLA BIOTECH INC (CA) 2025-09-17 — — EP disclosed
US-12358920-B2 Substituted pyrrolo[2,3-d]pyrimidines as selective CDK 4/6 inhibitors LUNELLA BIOTECH, INC. (CA) 2025-07-15 — — US disclosed
US-12319690-B2 Selective CDK 4/6 inhibitor cancer therapeutics LUNELLA BIOTECH, INC. (CA) 2025-06-03 — — US disclosed
CN-114901666-B Selective CDK4/6 inhibitor type cancer therapeutic drug 卢内拉生物技术有限公司 2025-01-14 — — CN disclosed
CN-118652252-A Selective CDK4/6 inhibitor type cancer therapeutic drug 卢内拉生物技术有限公司 2024-09-17 — — CN disclosed
CN-115023424-B Selective CDK4/6 inhibitor type cancer therapeutic drug 卢内拉生物技术有限公司 2024-07-02 — — CN disclosed
US-11964983-B2 Selective CDK4/6 inhibitor cancer therapeutics LUNELLA BIOTECH, INC. (CA) 2024-04-23 — — US disclosed
US-20240116942-A1 SELECTIVE CDK 4/6 INHIBITOR CANCER THERAPEUTICS LUNELLA BIOTECH, INC. (CA) 2024-04-11 — — US disclosed
EP-1734962-A2 COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS PainCeptor Pharma Corp. (CA) 2006-12-27 — — EP disclosed
EP-1718308-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PainCeptor Pharma Corp. (CA) 2006-11-08 — — EP disclosed
US-20060106077-A1 Pin1-Modulating compounds and methods of use thereof PINTEX PHARMACEUTICALS, INC. (US) 2006-05-18 — — US disclosed
WO-2006038070-A2 COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS PAINCEPTOR PHARMA CORPORATION (CA) 2006-04-13 — — WO disclosed
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2005-12-22 — — US disclosed
WO-2005076695-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2005-08-25 — — WO disclosed
WO-2005007123-A2 PIN1-MODULATING COMPOUNDS AND METHODS OF USE THEREOF PINTEX PHARMACEUTICALS, INC. (US) 2005-01-27 — — WO disclosed
EP-1109812-A2 PYRROLOBENZODIAZEPINES Spirogen Limited (GB) 2001-06-27 — — EP disclosed
WO-2000012508-A2 PYRROLBENZODIAZEPINES SPIROGEN LIMITED (GB) 2000-03-09 — — WO disclosed
US-4337270-A ANTIALLERGENS; ANTIANAPHYLACTIC AGENTS HISAMITSU PHARMACEUTICAL CO., INC. (JP) 1982-06-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11964983-B2 Selective CDK4/6 inhibitor cancer therapeutics CDK4, CDK6, CDKL4 TSHR 2843/4885CA12 4546/4885CA1 4810/4885
US-20060106077-A1 Pin1-Modulating compounds and methods of use thereof PIN1, FKBP14, PIN4 TSHR 4267/4885CA12 3283/4885CA1 2538/4885
US-12358920-B2 Substituted pyrrolo[2,3-d]pyrimidines as selective CDK 4/6 inhibitors CDK6, CDK4, CDKL4 TSHR 3777/4885CA12 4737/4885CA1 4559/4885
US-20250304591-A1 SUBSTITUTED PYRROLO[2,3-d]PYRIMIDINES AS SELECTIVE CDK 4/6 INHIBITORS CDK4, CDK6, CDKL4 TSHR 3835/4885CA12 4763/4885CA1 4694/4885
US-20240116942-A1 SELECTIVE CDK 4/6 INHIBITOR CANCER THERAPEUTICS CDK6, CDK4, CDKL4 TSHR 3325/4885CA12 4554/4885CA1 4622/4885
US-12319690-B2 Selective CDK 4/6 inhibitor cancer therapeutics CDK6, CDK4, CDKL4 TSHR 2090/4885CA12 4550/4885CA1 4636/4885
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 TSHR 1015/4885CA12 1557/4885CA1 717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.